| 摘要 |
PROBLEM TO BE SOLVED: To provide new CD37 antagonists for treating B cell malignancies and other diseases corresponding to exhaustion of CD37 positive B cells, and anti-CD37 antibodies having improved effector function.SOLUTION: Antibodies that are chimeric or humanized antibodies and are (a) mouse monoclonal antibodies binding to human CD37 and defined with (i) a variable heavy chain containing a specific amino acid sequence and (ii) a variable light chain containing a specific amino acid sequence, or (b) antibodies derived from humanized antibodies defined with (i) CDR containing the specific amino acid sequence in the variable heavy chain, (ii) CDR containing the specific amino acid sequence in the variable light chain, (iii) a frame work supporting the CDR and derived from human antibodies, and (iv) a regular heavy chain and light chain derived from human antibodies are provided. |
